U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07203547) titled 'Phase 4 Study of Laybon Tab. in Knee Osteoarthritis' on Sept. 24.
Brief Summary: This Phase 4, multicenter, randomized, double-blind, active-controlled, parallel study aims to evaluate the non-inferiority of Laybon Tab. compared to Layla Tab. (PMG Pharm Co., Ltd.) in patients with knee osteoarthritis. Participants will receive either Laybon Tab. or Layla Tab. for 8 weeks. The primary outcome is the change in knee pain during activity, assessed by a 100 mm pain VAS over the previous 24 hours.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Osteoarthritis, Knee
Osteoarthritis
Intervention:
DRUG: Layla Tab.
Lay...